IN2012DN02196A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02196A
IN2012DN02196A IN2196DEN2012A IN2012DN02196A IN 2012DN02196 A IN2012DN02196 A IN 2012DN02196A IN 2196DEN2012 A IN2196DEN2012 A IN 2196DEN2012A IN 2012DN02196 A IN2012DN02196 A IN 2012DN02196A
Authority
IN
India
Prior art keywords
treatment
relates
autoimmune
inflammatory disorders
epratuzumab
Prior art date
Application number
Other languages
English (en)
Inventor
Anna-Marie Novotney-Barry
Reginald Hulhoven
Gerald L Parker
Violet A Hoskin
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of IN2012DN02196A publication Critical patent/IN2012DN02196A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2196DEN2012 2009-09-18 2010-08-26 IN2012DN02196A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24379709P 2009-09-18 2009-09-18
PCT/EP2010/005225 WO2011032633A1 (en) 2009-09-18 2010-08-26 Treatment of autoimmune and inflammatory diseases with epratuzumab

Publications (1)

Publication Number Publication Date
IN2012DN02196A true IN2012DN02196A (enrdf_load_stackoverflow) 2015-08-21

Family

ID=43063209

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2196DEN2012 IN2012DN02196A (enrdf_load_stackoverflow) 2009-09-18 2010-08-26

Country Status (13)

Country Link
US (1) US20110070227A1 (enrdf_load_stackoverflow)
EP (1) EP2478012B1 (enrdf_load_stackoverflow)
JP (1) JP5816905B2 (enrdf_load_stackoverflow)
KR (1) KR20120100914A (enrdf_load_stackoverflow)
CN (1) CN102574920A (enrdf_load_stackoverflow)
AU (1) AU2010294905B2 (enrdf_load_stackoverflow)
BR (1) BR112012006035A2 (enrdf_load_stackoverflow)
CA (1) CA2774244A1 (enrdf_load_stackoverflow)
EA (1) EA026902B1 (enrdf_load_stackoverflow)
ES (1) ES2608661T3 (enrdf_load_stackoverflow)
IN (1) IN2012DN02196A (enrdf_load_stackoverflow)
MX (1) MX341117B (enrdf_load_stackoverflow)
WO (1) WO2011032633A1 (enrdf_load_stackoverflow)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080031684A (ko) 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
PL2789684T3 (pl) 2008-05-23 2017-06-30 Siwa Corporation Sposoby i kompozycje do ułatwiania regeneracji
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
PT4108671T (pt) 2010-10-01 2024-12-23 Modernatx Inc Nucleosídeos, nucleotídeos e ácidos nucleicos modificados e suas utilizações
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3978030A1 (en) 2012-04-02 2022-04-06 ModernaTX, Inc. Modified polynucleotides for the production of proteins associated with human disease
KR101995621B1 (ko) * 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
MX384006B (es) 2014-05-29 2025-03-14 Macrogenics Inc Moleculas de union tri-especificas que se unen especificamente a varios antigenos de cancer y metodos de uso de los mismos.
WO2016044252A2 (en) 2014-09-19 2016-03-24 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CA3021150C (en) 2016-02-19 2023-02-07 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
SG11201903521XA (en) 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3867280A4 (en) * 2018-10-18 2022-11-09 Sinomab Bioscience Limited METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
JP4286483B2 (ja) * 1999-06-09 2009-07-01 イムノメディクス, インコーポレイテッド B細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法
PT1558648E (pt) * 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
WO2007103469A2 (en) * 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
SI2032606T1 (sl) * 2006-05-30 2014-02-28 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof

Also Published As

Publication number Publication date
JP2013505205A (ja) 2013-02-14
CA2774244A1 (en) 2011-03-24
AU2010294905B2 (en) 2016-09-22
US20110070227A1 (en) 2011-03-24
JP5816905B2 (ja) 2015-11-18
AU2010294905A1 (en) 2012-04-05
KR20120100914A (ko) 2012-09-12
EA026902B1 (ru) 2017-05-31
WO2011032633A1 (en) 2011-03-24
EP2478012A1 (en) 2012-07-25
EA201270433A1 (ru) 2012-10-30
MX341117B (es) 2016-08-09
BR112012006035A2 (pt) 2019-09-24
EP2478012B1 (en) 2016-11-09
CN102574920A (zh) 2012-07-11
ES2608661T3 (es) 2017-04-12
MX2012002907A (es) 2012-04-30

Similar Documents

Publication Publication Date Title
IN2012DN02196A (enrdf_load_stackoverflow)
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
AP2011005984A0 (en) Antibodies specific to cadherin-17.
AU333675S (en) Bottle
AU333674S (en) Bottle
IL227081B (en) Modified antibody with improved half-life
AP2012006190A0 (en) Herbicide-tolerant plants.
AP2012006163A0 (en) Boron-containing small molecules as antiprotozoal agents.
CA143394S (en) Microwavable bag
MX350335B (es) Anticuerpos que enlazan alfa-v beta-8 integrina.
WO2012081924A3 (ko) 자전거
CA138917S (en) Beverage package
WO2010136104A3 (en) Anti-dandruff agents
MX2014001641A (es) Polisulfuros de organosilicio reticulados.
PL2602805T3 (pl) Obudowa urządzenia zabezpieczającego przed przepięciami i urządzenie zabezpieczające przed takimi przepięciami
WO2010007168A3 (en) Treatment of rheumatoid arthritis with mammal beta defensins
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
FR2948310B1 (fr) Etabli du genre table, repliable
TWI561442B (en) Strap with improved column stiffness
张芬英 et al. 都兰县洪水河铁矿地质特征及成因分析
GB201107632D0 (en) Elastic mount, in particular rubber-metal mount
CA141110S (en) Bottle
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
AP2012006243A0 (en) Saddle type vehicle.
AP2010000342S (en) Tusker bottle.